WO1996022532A1 - Immunoassay method and reagent involving suspendible carbon labelled bioaffine particles - Google Patents
Immunoassay method and reagent involving suspendible carbon labelled bioaffine particles Download PDFInfo
- Publication number
- WO1996022532A1 WO1996022532A1 PCT/SE1996/000042 SE9600042W WO9622532A1 WO 1996022532 A1 WO1996022532 A1 WO 1996022532A1 SE 9600042 W SE9600042 W SE 9600042W WO 9622532 A1 WO9622532 A1 WO 9622532A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- particles
- analyte
- ige
- carbon
- zone
- Prior art date
Links
- 239000002245 particle Substances 0.000 title claims abstract description 106
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 title claims abstract description 96
- 229910052799 carbon Inorganic materials 0.000 title claims abstract description 76
- 239000003153 chemical reaction reagent Substances 0.000 title description 11
- 238000003018 immunoassay Methods 0.000 title description 11
- 239000012491 analyte Substances 0.000 claims abstract description 64
- 238000000034 method Methods 0.000 claims abstract description 64
- 239000000376 reactant Substances 0.000 claims abstract description 54
- 239000013566 allergen Substances 0.000 claims abstract description 18
- 238000004458 analytical method Methods 0.000 claims abstract description 17
- 238000001514 detection method Methods 0.000 claims description 54
- 238000012360 testing method Methods 0.000 claims description 42
- 239000000725 suspension Substances 0.000 claims description 18
- 239000000427 antigen Substances 0.000 claims description 16
- 102000036639 antigens Human genes 0.000 claims description 16
- 108091007433 antigens Proteins 0.000 claims description 16
- 239000011159 matrix material Substances 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 12
- 230000027455 binding Effects 0.000 claims description 9
- 239000006229 carbon black Substances 0.000 claims description 5
- 239000011164 primary particle Substances 0.000 claims description 5
- 239000006231 channel black Substances 0.000 claims description 3
- 239000006232 furnace black Substances 0.000 claims description 3
- 239000006230 acetylene black Substances 0.000 claims description 2
- 239000006233 lamp black Substances 0.000 claims description 2
- 239000000523 sample Substances 0.000 description 56
- 239000012528 membrane Substances 0.000 description 24
- 239000012615 aggregate Substances 0.000 description 19
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 14
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 12
- 229940098773 bovine serum albumin Drugs 0.000 description 12
- 229920002678 cellulose Polymers 0.000 description 12
- 239000001913 cellulose Substances 0.000 description 12
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 11
- 239000000872 buffer Substances 0.000 description 11
- 239000005018 casein Substances 0.000 description 11
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 11
- 235000021240 caseins Nutrition 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 239000000020 Nitrocellulose Substances 0.000 description 10
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 10
- 229920001220 nitrocellulos Polymers 0.000 description 10
- 229940079938 nitrocellulose Drugs 0.000 description 10
- 239000013049 sediment Substances 0.000 description 10
- 230000035945 sensitivity Effects 0.000 description 8
- 239000000463 material Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000003556 assay Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 6
- 238000001825 field-flow fractionation Methods 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 239000008188 pellet Substances 0.000 description 6
- 229920000728 polyester Polymers 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 239000011534 wash buffer Substances 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 238000007792 addition Methods 0.000 description 5
- 230000000984 immunochemical effect Effects 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 206010054107 Nodule Diseases 0.000 description 4
- 239000004677 Nylon Substances 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 230000007815 allergy Effects 0.000 description 4
- 230000002860 competitive effect Effects 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229920001778 nylon Polymers 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000007790 solid phase Substances 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- 239000012131 assay buffer Substances 0.000 description 3
- 239000012496 blank sample Substances 0.000 description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 230000001788 irregular Effects 0.000 description 3
- 239000004816 latex Substances 0.000 description 3
- 229920000126 latex Polymers 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000012452 mother liquor Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000003896 Myeloperoxidases Human genes 0.000 description 2
- 108090000235 Myeloperoxidases Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000012911 assay medium Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000002327 eosinophilic effect Effects 0.000 description 2
- 239000011152 fibreglass Substances 0.000 description 2
- 238000001249 flow field-flow fractionation Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 108010074605 gamma-Globulins Proteins 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000002923 metal particle Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000036963 noncompetitive effect Effects 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 239000008279 sol Substances 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 241000238876 Acari Species 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- QDHHCQZDFGDHMP-UHFFFAOYSA-N Chloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 101710173438 Late L2 mu core protein Proteins 0.000 description 1
- 102000019298 Lipocalin Human genes 0.000 description 1
- 108050006654 Lipocalin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000004067 Osteocalcin Human genes 0.000 description 1
- 108090000573 Osteocalcin Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 108010015865 Transferrins Proteins 0.000 description 1
- 102000002070 Transferrins Human genes 0.000 description 1
- 108060005989 Tryptase Proteins 0.000 description 1
- 102000001400 Tryptase Human genes 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 239000012080 ambient air Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000003738 black carbon Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 108010074568 disialotransferrin Proteins 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000002706 hydrostatic effect Effects 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 239000013528 metallic particle Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229910052755 nonmetal Inorganic materials 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000002594 sorbent Substances 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- -1 urine Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54386—Analytical elements
- G01N33/54387—Immunochromatographic test strips
- G01N33/54388—Immunochromatographic test strips based on lateral flow
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
Definitions
- the analysis is concerned with determining the analyte content of a sample either qualitatively or quantatively with the aid of its bioaffine counterpart, by forming a complex between the counterpart and the analyte.
- a bioaffine reactant R x
- the analyte concentration of the sample can then be determined from the amount of complex-bound and/or non-complex-bound labelled reactant (R ⁇ and R 1 " respectively) .
- the invention uses suspendible carbon particles as a label.
- bioaffinity When the bioaffinity relates to antibodies and antigens/hapt- ens, one speaks about immunoassays or immunochemical assaying. When the bioaffinity concerns complementary oligo/ polynucleotides, one speaks about hybridization methods.
- the invention is adapted particularly to immunoassays.
- Particles are important in this context. According to known techniques, these particles will primarily have colloidal dimensions - be in the form of sols (i.e. normally 1-200 run and spherical and monodispersed) .
- Well- known particulate label groups are metal particles, non-metal particles (e.g. Si0 2 and carbon, latex and killed erythrocytes and bacteria) .
- labels that can be shown indirectly such as individual members of bioaffine pairs, e.g. biotin or (strept)avidin, hapten or antibodies, class-specific determinants in antibodies, etc.
- the indirectly detectable labels are often determined or assayed with the aid of their bioaffine counterparts labeled with labels that can be detected directly or indirectly.
- heterogenous and homogenous methods describe whether or not labelled reactants (R ) present in the complex are separated from non- complex-bound reactants (R ⁇ ') prior to assaying labelled reactants.
- Competitive methods utilize analyte analogs which compete with analytes in binding to a deficiency of reactants that have biospecific affinity to both the analyte and the analyte analog.
- Analyte analogs may be analytes that are labelled with or bound to an insoluble phase (solid phase) in the analysis medium.
- non-competitive methods are so-called sandwich methods in which the analyte is complexed between two or more reactants that exhibit biospecific affinity to mutually spaced epitopes on the analyte.
- India Ink is ink/drawing ink based on stably suspended carbon black (sol) (Hackhs Chemical Dictionary, 4th Ed., Ed. Julius Grant, McGraw-Hill Book Company, page 346) .
- EP 321,008 HBT Holland Biotechnology
- the patent emphasizes that the particles shall be in the form of sols, meaning that particles which are able to settle to form a sediment are not present in the particle preparations used.
- the patent makes particular mention to the production of sols by enclosing non-metallic colloidal primary particles in an inert hydrophilic envelope or by coupling reactants directly to the naked particle.
- sensitivity increases with increasing particle sizes, provided that the particle preparations used are monodispersed particles in sol form.
- the object of the present invention is to improve and simplify analysis methods of the kind defined in the introduction with the use of carbon particles as label groups.
- FIGURE 1 This illustrates an embodiment of the invention (test strip) for determining total IgE with the aid of a sandwich test using solid-phase bound anti-IgE antibodies (R 2 ) bound in a detection zone (Z j ) , labelled anti-IgE antibodies (R : ) and a control zone (Z 4 ) containing solid-phase bound anti-IgG antibodies (in our case anti-mouse IgG because R x is a mouse monoclonal) .
- the sample application zone (Z 3 ) is located in the lower part of the strip and the reagent R x is mixed with sample prior to its application to the strip at zone Z 3 .
- Transport zones (Z 2 ' and Z 2 " and Z 2 '") are located between the sample application zone (Z 3 ) and the detection zone Z ) , between the detection zone ( Z x ) and the control zone (Z 4 ) and between the control zone and a sucking body, respectively. That part of the strip which remains above the control zone may be understood as being a further transport zone (Z 2 ''').
- the arrow indicates the direction of flow in the strip.
- the reactants can be replaced as discussed below for different types of analytes. By replacing the solid-phase bound antibody R 2 for an antigen/hapten, the test will measure antigen/hapten-specific IgE (see the following examples) .
- the invention is based on the discovery that carbon particles of non-colloidal dimensions, preferably polydispersed and/or of irregular shape, function as labels and can even have a beneficial effect on the aforesaid analysis methods. Irregular particles have a greater surface/volume ratio per particle than spherical particles and thus give greater response or sensitivity to the analyses in which they are used as labels.
- One aspect of the invention includes methods of the kind defined in the introduction. These methods generally include
- the amount of particle-labelled reactant bound (R ⁇ ') or non-bound (Rx”) to the complex is determined qualitatively or quantitatively, wherein
- the determined quantity is taken as a measure of the presence or amount, respectively, of the amount of analyte in the sample.
- sensitivity increases with the amount o particles that can settle in accordance with the precedin paragraph.
- the amount of particles that ar able to settle is often > 0.1%, such as > 1%, preferably > 50%, with an upper limit of 100% (all percentages being w/ percentages, alternatively measured in accordance with th method described under the heading "Sensitivity as a functiono of the amount of settleable particles" in the experimental par of this document.
- the carbon particles have a weighted mean particl size of > 0.05 ⁇ m, preferably in the range of 0.2-5 ⁇ an more preferably in the range of 0.2-1 ⁇ ;
- the top value of the particle distribution gives a diamete which is > 0.1 ⁇ , preferably a diameter in the range o 0.2-5 ⁇ m and more preferably in the range of 0.2-1 ⁇ m;
- > 1%, such as > 10% or > 50%, with an upper limit of 100% of the particles, is > 0.1 ⁇ m and preferably lies in the range of 0.2-5 ⁇ m, and more preferably in the range of 0.2- 1 ⁇ m.
- Suitable particle sizes and percentages of settleable particles will vary in accordance with the test method applied, analyte, affinity and specificity of the bioaffine reagent used.
- the main rule is that, compared to a higher analyte concentration, a lower analyte concentration will demand a greater portion of particles that are > 200 n .
- low- concentration analytes ⁇ 10 "10 M
- FFF disk Centrifuge Photodensedimentometer
- Tests carried out hitherto have been effected with commercially available carbon-particle preparations in the form of primary aggregates of primary carbon nodules (primary particles) stably linked together, most likely covalently.
- the size of the nodules varies from carbon quality to carbon quality, but is normally in the range of 5-250 nm, with preference for 20-100 nm.
- the number of primary nodules contained in each primar aggregate also varies, and is 4-200 with regard to the most usable qualities, with preference to 6-75.
- stabl linked together is meant that the aggregates will not disintegrate under the conditions normally applicable to biospecific affinity reactions.
- the configuration of the primary aggregates may also vary from an elongated, branche configuration to more compact structures.
- the primary aggregates may, in turn, be secondarily aggregated to form larger units .
- these secondary aggregates are stable against disintegration, they can be used in the inventive analysis method provided that their sizes have no deleterious effect on the method applied.
- a number of potentially usable carbon qualities which fulfil the aforesaid definitions are commercially available from Degussa (Germany) and other manufacturers.
- Examples are carbon black, which is the collective name for furnace black, channel black, lamp black and acetylene black.
- the carbon content of these materials is usually from 85% and more, terminating at a content immediately beneath 100% (99.999%) (w/w) .
- the manufacturers have lowered the carbon content from 99-100% down to 85-99.9% (w/w) , by oxidative treatment of carbon black, among others. Oxidatively-treated forms of the carbon particles concerned have been found particularly usable in the inventive method, due to improved suspendibility when preparing the carbon-labelled reactant R x .
- the aforesaid carbon particles may be enclosed in polymeric envelopes and/or may carry bioaffine reactants or other groups that are able to take part in hydrophobic interactions, ion- binding, dipole, dipole-binding, etc.
- One or more particles may be enclosed in one and the same polymeric envelope or casing.
- Bioaffine reactants R x may be bound adsorptively directly t the naked aggregates or via an envelope in accordance with the previous paragraph. In this latter case, the possibility of covalent bonding is obvious and covalent bonding directly to the naked aggregates is also potentially feasible. Bioaffine reactants are best adsorbed on the carbon particles that are in suspended form.
- the labelled bioaffine reactant is exogenous to the sample, and normally also exogenous to the individual/organism/source from which the sample derives.
- sample pretreatments are a) sample dilution, b) sample concentration, c) analyte enrichment (e.g. removing disturbing substances) , d) pH-adjustment or adjustment by the use of other means, e) forming complexes between the analyte and a bioaffine counterpart, f) analyte modifications other than complex formation according to e) , and so on.
- Points e) and f) above imply that the analyte in steps i-iii refers to an analyte that is a modified version of the analyte in the original sample. All pretreatment processes are carried out so that the amount of analyte in the original sample and the amount of modified analyte in the pretreated sample will be unequivocally related to one another.
- Analysis conditions such as temperature, concentration, pH, sequence of additions of reactants and selection of reactants to be added are analogous with the conditions previously applied in respect of other labels used in assays which employ biospecific affinity reactions (immunochemical assaying, hybridizing methods, etc.).
- the assay medium is normally water, optionally mixed with water-miscible solvents.
- the temperature is in the range of 0- 40°C and the pH in the range of 4-10.
- the temperature will preferably lie in the range of 0-100°C.
- heterogenous methodology i.e. a technique in which labelled reactant R l ' included in the complex is separated physically from labelled reactant R 1 " which is not included in the complex, prior to assaying one or both of said reactants.
- said reactants are separated by using a phase (matrix) which is insoluble in the assay medium and which has a bioaffine reactant bound thereto, to achieve selective partition of the complex-bound labelled reactant to the matrix before separation takes place.
- the insoluble phase (the matrix) used in heterogenous variants of the invention may have the form of a strip, plate, porous continuous matrix (monolith) , hydrophilic particles, preferably porous particles, membranes, diaphragms, etc.
- the prerequisites for separating, assaying and correlating analytes as a function of labelled reactants are the same as those applicable in known techniques, with the exception of being adapted to the fact that according to the invention, the label group consists of particles.
- the heterogenous method according to the invention considered most practical at present utilizes porous matrices, either in the form of particle-packed beds or in the form of monoliths (self-coherent matrices) .
- Monolith-type matrices may be given the form of test strips or membranes which include a detection zone (Z x ) for the detection of formed complexes.
- the test strip or membrane will also normally include one or more zones (e.g. Z 2 ' and Z 2 ") for the transportation of sample, reactant (e.g. R , washing solution, etc., to and/or from respective detection zones, and a sample application zone (Z 3 ) , and optionally further zones Z 4 , Z 5 , etc.
- the transport zone Z 2 ' lies between the sample application zone and the detection zone.
- the zones need not necessarily be comprised of the same material. For instance, it is often practical to choose material with regard to the function of the zone. See below.
- the detection zone Z x contains a bioaffine reactant (R 2 ) which is stably bound to the matrix and which is capable of capturing labelled reactant R x in a quantity which is a function of the analyte content of the sample.
- R 2 bioaffine reactant
- the detection zone will blacken. Blackening of the detection zone can be shown both quantatively and qualita ⁇ tively, in several ways, preferably visually although perhaps more preferably, and more reliably, through the medium of computer-based picture or image analysis in accordance with Amerongen, et al (J. Biotechnol. 30 (1983), pp. 185-189, and Clin. Chim. Acta 229 (1994), pp. 67-75).
- the stably bound reactant R 2 and the labelled reactant R x are both directed against the analyte (sandwich test) ;
- the bioaffine reactant R 2 stably anchored to the detection zone is directed against epitopes present in both analyte and reactant R x (R x is an analyte analog) (competitive test) .
- R 2 being stably anchored in the detection zone is meant to imply that R 2 will not be eluated by the various assay-buffers that pass through.
- the reactant R 2 is anchored in a conventional manner, i.e. covalently bound or bound via adsorption (normally via hydrophobic forces) .
- the simplest heterogenous variant of the invention using a porous matrix in the form of a packed particle bed or in the form of a monolith has only one detection zone Z 1 , this zone also functioning as a sample application zone.
- Reagent e.g. R x
- washing solution are applied directly to the detection zone and leave the matrix immediately after having passed through said zone.
- the detection zone is in contact with one or two transport zones (Z 2 ' and Z 2 ") for transportation to and from the detection zone respectively.
- Z 2 " is preferably highly absorbent so as to facilitate liquid transportation.
- the reactant R x can be contacted with the detection zone in a number of different ways. It is generally preferred to bring reactant R x into contact (incubated) with analyte so that they are able to wander into the detection zone (Z x ) together. One variant is to pre-incubate/mix the sample with reactant R x prior to its application to the sample application zone. Reactant R j may also be pre-dispensed in the transport zone Z 2 ' or in the sample application zone Z 3 , so that R j is transported together with analyte to the detection zone Z x .
- Conceivable alternatives include pre-dispensing the reactant R x in the detection zone Z x or in a zone which is separated physically from the hitherto mentioned zones, or is applied directly to the detection zone Zj subsequent to having bound the analyte thereto.
- the biospecific reactants R 2 which is stably linked to the detection zone is not capable of binding directly to the analyte. It may then be neccessary to preincubate, e.g. the sample or the detection zone Z or the transportation zone Z 2 ', with a bifunctional affinity reagent that is capable of creating a link between the analyte and R 2 .
- the sample can be transported from different zones to the detection zone by capillary forces when the matrix is initially dry to a substantial extent.
- a suction body may be included in the vicinity of the transport zone Z 2 ' (transportation from detection zone) .
- Transportation can also be effected with the aid of an electric field.
- the sample application zone is located at a higher level than the detection zone, transportation can be effected with the aid of hydrostatic pressure, particularly in the case of porous matrices in the form of membranes .
- Washing of the detection zone after applying different reagents will often require a surplus liquid absorption capacity in a position downstream of the detection zone. This can be achieved by increasing the volume of the transport zone Z 2 " or by placing a highly absorbent matrix in liquid-flow contact therewith.
- the sample application zone Z 3 often has the form of a porous matrix which possesses good water retention properties and, at the same time, is well capable of releasing water to the transport zone Z 2 ' during the analysis process .
- the matrix may be sufficiently hydrophilic to permit the transportation of liquid.
- the matrix shall have a porosity which will enable the carbon particles to wander from the sample application zone to the detection zone.
- the pore size shall be greater than the size of the carbon particles.
- the pore size will preferably lie in the range of 0.4-100 ⁇ m, in order to obtain an acceptable function of hydrophilic matrices.
- Nylon, nitrocellulose and cellulose were used in the detection zone. Nylon and cellulose have been used for reactants R 2 that are anchored covalently, and nitrocellulose has been used for reactants R 2 that have been anchored adsorptively.
- the material used in the sample application zone was the same as the material used in the transport zone, optionally in combination with a cellulose filter and/or fiberglass filter as a liquid reservoir.
- Particle size, porosity and hydrophobicity can be optimized with respect to one another by simple experimentation in ready manner. See the experimental part.
- the most preferred embodiment geometrically in the case o porous matrices is a test strip in which the sample applicatio zone, transport zone and detection zone are placed laterall after one another, with the possibility of liqui transportation therebetween.
- th control zone contains a bioaffine reactant which binds to R 1( the control zone will be blackened in response to negativ samples (and also in response to positive samples) , therewit providing a function control .
- the matrix will preferably be white in colour, even though pale nuances of other colours which provide good contrasts wit black carbon particles are acceptable.
- R x and R 2 may b antibodies that are directed against physically spaced epitope on the analyte, which is an antigen or a hapten having at leas two epitopes.
- This technique is used to determine primaril high molecular weight, bio-organic molecules, such as proteins, e.g. Ig of a given class (IgA, IgD, IgE, IgG and IgM) .
- one of R x and R 2 is an antigen/hapte and the other is an antibody directed against a class-specific determinant (IgA, IgD, IgE, IgG and IgM) .
- R x is an analyte analog and R 2 is an antibody directed against both the analyte and the analyte analog.
- This technique is primarily directed towards low-molecular bio-organic molecules and can be used to assay high molecular weight proteins, such as IgE.
- the inventive method has been developed primarily for assaying serum/plasma levels levels of total-IgE and allergen-specific IgE for the purpose of allergy diagnosis, and corresponding methods in relation to other Ig classes.
- the ranges of IgE concentration in this type of use was 10 "10 - 10 "7 M total IgE/1 serum and 10 "12 - 10 "9 M allergen-specific IgE/1 serum respectively (i.e. both total IgE and allergen-specific IgE are low-concentration analytes) .
- antibody as used here includes intact antibodies and antigen-binding antibody fragments.
- antigen as used here includes the antigen as such, hapten and antigen fragments that exhibit antibody-binding activity.
- Another aspect of the invention is an immunoreagent which is labelled with particles and chosen from the group comprising IgE, anti-IgE antibody and allergen, including IgE-binding epitopes thereof.
- This aspect is characterized in that the particles are carbon particles.
- the particles are defined in the same way as those used in the inventive method.
- the invention can be used in clinical diagnosis (including therapy monitoring processes) , to which the aforesaid particle ranges are directly applicable and in many cases necessary.
- Typical samples are: Cerebro Spinal fluid (CSF) , saliva, lachrymal fluid, urine, blood (plasma and serum) , etc.
- Diagnostic areas of particular interest are assays in which an analyte is assayed in order to follow up a treatment (monitoring) and to diagnose various inflammatory conditions, such as asthma, and allergy-related conditions, and prolonged alcohol over-consumption.
- relevant analytes are antigen/allergen-specific antibodies of different classes (particularly IgA, IgD, IgE, IgG and IgM) , total levels of respective Ig classes, eosinophilic cationic protein (ECP) , eosinophilic protein X (EPX) , myeloperoxidase (MPO) , human neutrophilic lipocalin (HNL) , lysozyme, tryptase, interleukins (IL-5, IL-6, IL-8), hyaluronic acid (HA), osteocalcin, etc.
- ECP eosinophilic cationic protein
- EPX eosinophilic protein X
- MPO
- CDT carbohydrate deficient transferrins
- asialotransferrin and disialotransferrin are important analytes. This does not mean, of course, that the inventive method cannot also be applied in the diagnosis of other illnesses, such as cancer, hormonal disorders, etc.
- the invention can also be applied in conjunction with quality controls in the production of substances which exhibit biospecific affinity.
- concentrations are often much higher and completely different requirements are placed on sensitivity and specificity.
- the demand placed on the carbon particles is also correspondingly lower, meaning that suspendibility will often suffice.
- This applies, inter alia, to IgE, anti-IgE antibodies, allergen and allergen epitopes ( haptens deriving from allergens) which bind to antibodies (particularly to IgE) and other earlier mentioned analytes and antibodies directed thereagainst.
- the invention can also be applied in environmental analyses, for instance for determining the presence of allergens in ambient air. Allergens normally derive from pollen, mites, cats, etc., and often have a protein structure.
- the invention has primarily been developed for measuring low- concentration analytes by which are meant analytes that are measured in a range extending wholly or partly below 10" 10 , i.e. concentrations within 1-I0xl0 ⁇ 10 belong to the low- concentration range.
- concentrations within 1-I0xl0 ⁇ 10 belong to the low- concentration range.
- This ranges refer to the concentrations of the analyte as it is present in its natural environment (CSF, plasma, serum, whole blood, urine, lachrymal fluid, saliva etc) .
- Carbon suspension (mother liquor) : About 500 mg of carbon particles were suspended in 50 ml of a 5 mM borate buffer at pH 8.5 and sonicated for thirty minutes. Prior to the adsorption of protein on the carbon particles, the suspension was diluted to 1 mg/ml and sonicated for a further three minutes. The carbon quality used will be apparent from the following description of respective tests.
- borate buffer 0.1 M, pH 8.5, containing 1% BSA and 0.05% NaN 3 , with intermediate centrifugation at 16,000 x g.
- the sediment was diluted with borate buffer (0.1 M, pH 8.5, 1% BSA, 0.05% NaN 3 ) to a carbon content of 500 ⁇ g/ml .
- the quantities used were adapted so that the anti-IgE antibody concentration was 25-50 ⁇ g/ml in the final solution.
- the centrifugation times varied with different types of carbons.
- Test strip 1 A nitrocellulose membrane (Schleicher and Schuell, Germany, 8 ⁇ m) was laid against a stiff pre-gummed polyester sheet. An anti-IgE antibody solution was then sprayed onto the sheet in a line (detection zone) parallel with one side of the sheet, and an anti-Fc mouse IgG antibody solution was sprayed onto the sheet in a line (control zone) parallel with and well-spaced from the first line. The membrane was allowed to dry and was then clipped into strips measuring 0.8 cm x 4 cm (with the antibody lines parallel with the short ends of the strips) .
- a filter paper (Whatman cellulose 17 CHr, England, measuring 0.8 cm x 0.8 cm (sample application zone)) was placed at the short end of the strip (at the bottom of the strip) on the same side as the detection zone.
- a suction filter (Whatman cellulose 17 CHr, 2 cm x 2 cm) was placed at the other end of the strip (at the top of the strip) .
- the control zone was omitted in certain tests. The precise measurements varied slightly from case to case.
- Test strip 2 was analogous with test strip 1 with the exception that the detection zone was comprised of a strip of cellulose paper (3 mm in width) to which mite allergen was covalently bound (CNBr coupling) , the strip was clipped from a mite disc (dl allergen disc) , Kabi Pharmacia Diagnostics AB, Sweden) . The nitrocellulose membrane had been cut-off in the position of the detection zone, and the mite strip gummed to the test strip with opposite ends overlapping (membrane on top and mite strip beneath in the lower part of the detection zone (the part facing in the flow direction)) and vice versa in the upper part.
- the detection zone was comprised of a strip of cellulose paper (3 mm in width) to which mite allergen was covalently bound (CNBr coupling)
- the strip was clipped from a mite disc (dl allergen disc) , Kabi Pharmacia Diagnostics AB, Sweden) .
- the nitrocellulose membrane had been cut-off in the position of the detection zone
- Test strip 3 A nylon membrane. Anti-IgE antibodies, birch allergens or casein were bound covalently in the detection zone.
- Mite-specific IgE 38 ⁇ l of a positive human serum containing
- Casein-specific IgE 45 ⁇ l of a positive human serum (RAS positive with regard to casein) was diluted with normal huma serum to 20 kU/1 of casein-specific IgE per litre or of a blan sample (human serum ⁇ 0.35 kU IgE/1) and mixed with 7.5 ⁇ l (5 g carbon) of a suspension of carbon particles into which casei had been adsorbed in accordance with the aforegoing, and the applied directly to the sample application zone on test stri 1. Subsequent to absorption of the sample into the zone, a was was initiated in the same manner as that for total IgE. Th positive sample resulted in unequivocal blackening of th detection zone. No blackening was observed in the case of th blank sample.
- Aggregate labelled anti-IgE antibodies Tests were carried ou with 125 -anti-IgE antibodies labelled in accordance with th Chloramine T-method. The labelled antibody was then adsorbed o carbon particles (sp 100 (Degussa, Germany) in accordance wit the above method. Mother liquors were stored in a refrigerato at +4°C and all of the particles were found to have settle after two calendar days. Suspensions containing adsorbe antibodies were centrifuged at different G numbers, to obtai fractions of different sizes (in the form of pellets an supernatants) .
- Respective pellets were re-suspended and allowed to settle a room temperature over a period of eleven calendar days Supernatants were also allowed to settle under the sam conditions. The radioactivity of the sediments was determine and taken as a measurement of the portion/percentage o settleable particles in respective fractions. The results ar set forth in Table 1 below.
- Signal strength as a function of carbon aggregate sizes The procedure applied was in accordance with standard protocol for lateral immunoassay chromatography.
- the samples used were IgE- standards (0.5-50 kU IgE/1, 6% BSA, 50 mM phosphate buffer, pH 7.5, 0.05% NaN 3 ) . Because the low measuring range is the range of most interest when testing allergen-specific IgE, the signal strength was compared at 0.5 kU IgE/1. The signal strength was converted to relative measurement values (signal strength:mean signal).
- the fractions were divided into three groups: supernatants (3 in number) , non-centrifuged suspensions (2 in number) and pellets, sediment (3 in number) . The results are set forth in Table 1.
- the signal strength wa compared at 0.5-1 kU/1 with a plurality of carbon sorts.
- the measured values were converted to relative values (signal strength:mean signal) .
- the carbon sorts were divided into three groups with 6-7 carbon sorts in each group, depending on the function of the low IgE values in the assay.
- the tendency of the carbon particles on which anti-IgE antibodies had been adsorbed to settle (+4°C for a month) from the suspension was taken as a measurement of aggregate size. A suspension from which all carbon particles had settled to provide a complete sediment was given the value of 4+, whereas a suspension which resulted in no sediment was given the value 0+.
- Table II The results are set forth in Table II below.
- the test protocol was the same as that used for total IgE.
- Two analysis series were carried out with the same amount of carbon of two different carbon sorts (sp 4 and sp 100 respectively) .
- the IgE contents of the samples were 1, 5, 20 and 100 kU/1.
- Standard curves for respective carbon sorts show that sp 100 gives a higher signal than sp 4 in the case of low IgE concentrations, but that on a molar basis sp 4 carried more reagent, resulting in a higher signal at higher concentrations
- the tendency of larger particles/aggregates to produce stronge signals was also observed when corresponding comparisons were made on different membranes.
- Sp 100 produces with:
- the diameter of aggregate sizes for sp 100 and sp 4 were determined by:
- Weighted mean values are 200 nm for sp 100 and 85 nm for sp 4.
- Anti-IgE (Pharmacia Diagnostics, Uppsala, Sweden) had previously been adsorbed in a thin line (1x5 mm) 2 cm from the application end (detection zone) .
- a sucking cellulose pad (5x15 mm Whatha cellulose 17 Chr) was placed at the top of the nitro-cellulose membrane, downstream the adsorbed anti-IgE.
- Casein had previously been adsorbed in a thin line (1x5 mm, detection zone) 2 cm from the application end.
- a sucking cellulose pad (5x15 mm Whatham cellulose 17 Chr) was placed at the top of the nitro-cellulose membrane, downstream the adsorbed casein.
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP96901591A EP0804733A1 (en) | 1995-01-20 | 1996-01-18 | Immunoassay method and reagent involving suspendible carbon labelled bioaffine particles |
JP8522207A JPH11505603A (en) | 1995-01-20 | 1996-01-18 | Immunoassays and reagents containing suspended carbon labeled bioaffine particles |
AU45928/96A AU4592896A (en) | 1995-01-20 | 1996-01-18 | Immunoassay method and reagent involving suspendible carbon labelled bioaffine particles |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9500184-8 | 1995-01-20 | ||
SE9500184A SE9500184D0 (en) | 1995-01-20 | 1995-01-20 | Assay method utilizing biospecific affinity reactions and labeled reactant as well as reagents to be used in preferred embodiment |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996022532A1 true WO1996022532A1 (en) | 1996-07-25 |
Family
ID=20396890
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/SE1996/000042 WO1996022532A1 (en) | 1995-01-20 | 1996-01-18 | Immunoassay method and reagent involving suspendible carbon labelled bioaffine particles |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0804733A1 (en) |
JP (1) | JPH11505603A (en) |
AU (1) | AU4592896A (en) |
CA (1) | CA2210794A1 (en) |
SE (1) | SE9500184D0 (en) |
WO (1) | WO1996022532A1 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998032019A1 (en) * | 1997-01-14 | 1998-07-23 | Akzo Nobel N.V. | Device for detecting an analyte and an analytical method |
WO1998052044A1 (en) * | 1997-05-15 | 1998-11-19 | Clinical Diagnostic Chemicals Limited | Immunoassay apparatus for diagnosis |
WO1998053321A1 (en) * | 1997-05-21 | 1998-11-26 | Merck Patent Gmbh | STRIP TEST FOR DIAGNOSING ALLERGIES $i(IN-VITRO) |
WO1999060402A1 (en) * | 1998-04-30 | 1999-11-25 | Pharmacia & Upjohn Diagnostics Ab | Ligand binding assay and kit with a separation zone for disturbing analytes |
WO2000036418A1 (en) * | 1998-12-11 | 2000-06-22 | Axis-Shield Asa | Dipstick for carbohydrate-free transferrin assay |
JP2002509253A (en) * | 1997-12-30 | 2002-03-26 | ファルマシア・アンド・アップジョン・ディアグノスティクス・アクチエボラーグ | Analytical method using particles and test kit for performing this method |
US6916666B1 (en) | 1997-12-30 | 2005-07-12 | Pharmacia Diagnostics Ag | Method using a new calibrator and a device and test kit including the calibrator |
WO2007067680A2 (en) * | 2005-12-05 | 2007-06-14 | Guava Technologies | Particle-based analyte characterization |
US20110076698A1 (en) * | 2008-06-10 | 2011-03-31 | Intec Products, Inc. (Xiamen) | method of quickly determining human abo/rh/mn blood type and a test kit thereof |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3074853A (en) * | 1961-06-22 | 1963-01-22 | Hynson Westcott & Dunning Inc | Serological test card with color solid as visualizing agent |
US3928628A (en) * | 1972-07-06 | 1975-12-23 | Wojewodzka Stacja Krwiodawstwa | Process for the preparation of a serological carrier |
EP0239318A1 (en) * | 1986-03-18 | 1987-09-30 | IL HOLDING S.p.A. | Assay employing binding pair members on particles and on a filter or membrane |
EP0299428A2 (en) * | 1987-07-13 | 1989-01-18 | Abbott Laboratories | Process for immunochromatography with colloidal particles |
EP0321008A1 (en) * | 1987-11-19 | 1989-06-21 | H.B.T. Holland Biotechnology B.V. | Immunodetermination using non-metallic labels |
WO1989011102A1 (en) * | 1988-05-04 | 1989-11-16 | Angenics, Inc. | Capillary flow device and double capture assay method |
GB2239314A (en) * | 1989-12-18 | 1991-06-26 | Princeton Biomeditech Corp | Immunochemical label and test device |
-
1995
- 1995-01-20 SE SE9500184A patent/SE9500184D0/en unknown
-
1996
- 1996-01-18 CA CA002210794A patent/CA2210794A1/en not_active Abandoned
- 1996-01-18 JP JP8522207A patent/JPH11505603A/en active Pending
- 1996-01-18 AU AU45928/96A patent/AU4592896A/en not_active Abandoned
- 1996-01-18 WO PCT/SE1996/000042 patent/WO1996022532A1/en not_active Application Discontinuation
- 1996-01-18 EP EP96901591A patent/EP0804733A1/en not_active Withdrawn
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3074853A (en) * | 1961-06-22 | 1963-01-22 | Hynson Westcott & Dunning Inc | Serological test card with color solid as visualizing agent |
US3928628A (en) * | 1972-07-06 | 1975-12-23 | Wojewodzka Stacja Krwiodawstwa | Process for the preparation of a serological carrier |
EP0239318A1 (en) * | 1986-03-18 | 1987-09-30 | IL HOLDING S.p.A. | Assay employing binding pair members on particles and on a filter or membrane |
EP0299428A2 (en) * | 1987-07-13 | 1989-01-18 | Abbott Laboratories | Process for immunochromatography with colloidal particles |
EP0321008A1 (en) * | 1987-11-19 | 1989-06-21 | H.B.T. Holland Biotechnology B.V. | Immunodetermination using non-metallic labels |
WO1989011102A1 (en) * | 1988-05-04 | 1989-11-16 | Angenics, Inc. | Capillary flow device and double capture assay method |
GB2239314A (en) * | 1989-12-18 | 1991-06-26 | Princeton Biomeditech Corp | Immunochemical label and test device |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998032019A1 (en) * | 1997-01-14 | 1998-07-23 | Akzo Nobel N.V. | Device for detecting an analyte and an analytical method |
WO1998052044A1 (en) * | 1997-05-15 | 1998-11-19 | Clinical Diagnostic Chemicals Limited | Immunoassay apparatus for diagnosis |
WO1998053321A1 (en) * | 1997-05-21 | 1998-11-26 | Merck Patent Gmbh | STRIP TEST FOR DIAGNOSING ALLERGIES $i(IN-VITRO) |
US6916666B1 (en) | 1997-12-30 | 2005-07-12 | Pharmacia Diagnostics Ag | Method using a new calibrator and a device and test kit including the calibrator |
US7405084B1 (en) | 1997-12-30 | 2008-07-29 | Phadia Ab | Analytical method using particles and test kit for performing the method |
JP2002509253A (en) * | 1997-12-30 | 2002-03-26 | ファルマシア・アンド・アップジョン・ディアグノスティクス・アクチエボラーグ | Analytical method using particles and test kit for performing this method |
WO1999060402A1 (en) * | 1998-04-30 | 1999-11-25 | Pharmacia & Upjohn Diagnostics Ab | Ligand binding assay and kit with a separation zone for disturbing analytes |
US6737278B1 (en) | 1998-04-30 | 2004-05-18 | Pharmacia & Upjohn Diagnostic Ab | Ligand binding assay and kit with a separation zone for disturbing analytes |
US6716641B1 (en) | 1998-12-11 | 2004-04-06 | Axis-Shield Asa | Dipstick for carbohydrate-free transferrin assay |
WO2000036418A1 (en) * | 1998-12-11 | 2000-06-22 | Axis-Shield Asa | Dipstick for carbohydrate-free transferrin assay |
WO2007067680A2 (en) * | 2005-12-05 | 2007-06-14 | Guava Technologies | Particle-based analyte characterization |
WO2007067680A3 (en) * | 2005-12-05 | 2007-08-23 | Guava Technologies | Particle-based analyte characterization |
US20110076698A1 (en) * | 2008-06-10 | 2011-03-31 | Intec Products, Inc. (Xiamen) | method of quickly determining human abo/rh/mn blood type and a test kit thereof |
Also Published As
Publication number | Publication date |
---|---|
AU4592896A (en) | 1996-08-07 |
CA2210794A1 (en) | 1996-07-25 |
EP0804733A1 (en) | 1997-11-05 |
JPH11505603A (en) | 1999-05-21 |
SE9500184D0 (en) | 1995-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4579414B2 (en) | Kit with ligand binding assay and inhibitory analyte separation region | |
DE3687589T2 (en) | FIXED BODY SYSTEM FOR USE IN LIGAND RECEPTOR EXAMINATIONS. | |
US5158869A (en) | Analyte determination using comparison of juxtaposed competitive and non-competitive elisa results and device therefore | |
FI92883C (en) | Test procedure and reagent kit for this | |
US5716854A (en) | Solid phase binding assay | |
JP2005189246A (en) | Immunochromatographic assay of controlled sensitivity | |
JP2541793B2 (en) | Method for detecting Chlamydia trachomatis antigen and Neisseria gonorrhoeae antigen | |
EP0564494B1 (en) | Test method and reagent kit therefor | |
JP3005303B2 (en) | measuring device | |
GB2191577A (en) | Layered immunoassay using antibodies bound to transport particles to determine the presence of an antigen | |
JP3833358B2 (en) | A homogeneous detection method for the measurement of subpopulations of analytes | |
EP0804733A1 (en) | Immunoassay method and reagent involving suspendible carbon labelled bioaffine particles | |
JP2001033454A (en) | Method and apparatus for determining substance to be detected on porous solid-phase ligand measuring test piece | |
US5529901A (en) | Method for determining the presence or amount of analyte using a stable colloidal carbon sol | |
JPH09500962A (en) | Testing equipment | |
WO1999064863A9 (en) | Colloidal colorimetric flow through and lateral flow assays utilizing soluble submicron particles | |
CA2149062C (en) | Immunoassays using a carbon sol label | |
JPH06505803A (en) | Multitest immunochemical reagents and methods for their use | |
WO1997023774A1 (en) | Particle assisted immunoassay | |
IT8922239A1 (en) | IMMUNOLOGICAL REACTIVE, PROCEDURE TO PREPARE IT AND KIT FOR IMMUNOLOGICAL ANALYSIS. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2210794 Country of ref document: CA Ref country code: JP Ref document number: 1996 522207 Kind code of ref document: A Format of ref document f/p: F Ref country code: CA Ref document number: 2210794 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1996901591 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref country code: US Ref document number: 1997 875482 Date of ref document: 19971007 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 1996901591 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1996901591 Country of ref document: EP |